Celldex Therapeutics, Inc. (CLDX) Shares Sold by QS Investors LLC

QS Investors LLC decreased its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 0.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 438,739 shares of the biopharmaceutical company’s stock after selling 1,566 shares during the period. QS Investors LLC owned approximately 0.34% of Celldex Therapeutics worth $1,084,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Voya Investment Management LLC grew its position in shares of Celldex Therapeutics by 17.4% during the second quarter. Voya Investment Management LLC now owns 50,535 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 7,499 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Celldex Therapeutics by 69.0% in the second quarter. Dimensional Fund Advisors LP now owns 832,186 shares of the biopharmaceutical company’s stock worth $2,056,000 after acquiring an additional 339,639 shares in the last quarter. Virtu KCG Holdings LLC grew its position in Celldex Therapeutics by 458.6% in the second quarter. Virtu KCG Holdings LLC now owns 117,770 shares of the biopharmaceutical company’s stock worth $291,000 after acquiring an additional 96,687 shares in the last quarter. Vanguard Group Inc. grew its position in Celldex Therapeutics by 7.8% in the second quarter. Vanguard Group Inc. now owns 9,774,858 shares of the biopharmaceutical company’s stock worth $24,143,000 after acquiring an additional 708,095 shares in the last quarter. Finally, Northern Trust Corp grew its position in Celldex Therapeutics by 12.2% in the second quarter. Northern Trust Corp now owns 2,020,797 shares of the biopharmaceutical company’s stock worth $4,992,000 after acquiring an additional 219,661 shares in the last quarter. Hedge funds and other institutional investors own 56.69% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Celldex Therapeutics, Inc. (CLDX) Shares Sold by QS Investors LLC” was first published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US and international copyright and trademark laws. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/2957199/celldex-therapeutics-inc-cldx-shares-sold-by-qs-investors-llc.html.

Shares of Celldex Therapeutics, Inc. (NASDAQ CLDX) opened at 3.10 on Friday. The company’s market cap is $397.86 million. Celldex Therapeutics, Inc. has a 1-year low of $2.20 and a 1-year high of $5.02. The stock’s 50 day moving average is $2.72 and its 200 day moving average is $2.78.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.05. The firm had revenue of $3.83 million during the quarter, compared to analysts’ expectations of $1.21 million. Celldex Therapeutics had a negative net margin of 1,318.94% and a negative return on equity of 51.87%. The firm’s quarterly revenue was up 175.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.32) EPS. On average, analysts predict that Celldex Therapeutics, Inc. will post ($1.04) earnings per share for the current year.

Several research firms recently commented on CLDX. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, August 1st. ValuEngine lowered Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Zacks Investment Research downgraded shares of Celldex Therapeutics from a “buy” rating to a “sell” rating in a research note on Monday, July 17th. Aegis reissued a “buy” rating on shares of Celldex Therapeutics in a research note on Thursday, June 29th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $9.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, September 26th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $5.88.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.